Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
暂无分享,去创建一个
O. Elemento | A. Sboner | Yuzhuo Wang | H. Beltran | J. Mosquera | D. Rickman | V. Conteduca | K. Isse | L. Puca | E. Dardenne | S. Tagawa | D. Nanus | M. Sigouros | L. Saunders | H. Pan | V. Sailer | R. Dittamore | Judy Hess | A. Vosoughi | S. Motanagh | A. Donoghue | Katie Gavyert | M. Kearney | L. Fernandez | Samaneh A Motanagh | Michael Sigouros
[1] J. Hartley,et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine , 2018, Scientific Reports.
[2] Joshua M. Stuart,et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Lorente,et al. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Dong Gao,et al. Patient derived organoids to model rare prostate cancer phenotypes , 2018, Nature Communications.
[5] Jason S. Lewis,et al. Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. , 2018, Cancer research.
[6] David S. K. Lu,et al. Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. , 2017, Cancer research.
[7] Michael D. Nyquist,et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.
[8] Anne-Katrin Emde,et al. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. , 2017, JCO precision oncology.
[9] J. McKenney,et al. Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC). , 2017 .
[10] Henry W. Long,et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.
[11] M. Rubin,et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.
[12] Luc Girard,et al. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.
[13] X. Zhang,et al. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. , 2016, The Journal of clinical investigation.
[14] Matteo Benelli,et al. Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.
[15] H. Beltran,et al. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer , 2015, Clinical Cancer Research.
[16] T. Buhl,et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas , 2015, International journal of cancer.
[17] C. Rudin,et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo , 2015, Science Translational Medicine.
[18] Martin Vingron,et al. Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.
[19] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[20] M. Landers,et al. Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization , 2015, Journal of circulating biomarkers.
[21] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[22] Tao Wang,et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers , 2014, Proceedings of the National Academy of Sciences.
[23] Paul Theodor Pyl,et al. HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[24] M. Rubin,et al. Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.
[25] M. Rubin,et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. , 2014, Cancer research.
[26] K. Kaestner,et al. Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2 , 2013, The Prostate.
[27] Francine E. Garrett-Bakelman,et al. Base-Pair Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic Landscapes in Acute Myeloid Leukemia , 2012, PLoS genetics.
[28] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[29] David R. Kelley,et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.
[30] M. Gerstein,et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.
[31] Felix Krueger,et al. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications , 2011, Bioinform..
[32] M. Walker,et al. Repression of Androgen Receptor Activity by HEYL, a Third Member of the Hairy/Enhancer-of-split-related Family of Notch Effectors* , 2011, The Journal of Biological Chemistry.
[33] E. Kremmer,et al. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. , 2011, Human molecular genetics.
[34] Hervé Rouault,et al. Mechanism and Significance of cis-Inhibition in Notch Signalling , 2011, Current Biology.
[35] Zhijun Tang,et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. , 2006, Developmental biology.
[36] Y. Yatabe,et al. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. , 2005, Cancer research.
[37] J. Boulter,et al. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands , 2005, The Journal of cell biology.
[38] M. Walker,et al. Hey1, a Mediator of Notch Signaling, Is an Androgen Receptor Corepressor , 2005, Molecular and Cellular Biology.
[39] S. Varambally,et al. JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence , 2004, Cancer Research.
[40] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] R. Beddington,et al. Axial skeletal defects caused by mutation in the spondylocostal dysplasia/pudgy gene Dll3 are associated with disruption of the segmentation clock within the presomitic mesoderm. , 2002, Development.
[42] M. Rubin,et al. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. , 2000, Human pathology.
[43] C. Rudin,et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. , 2017, The Lancet. Oncology.
[44] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..